Patient Selection Criteria Coverage eligibility will be considered for deep brain stimulation (DBS) of the thalamus when the following criteria are met: Disabling, medically unresponsive tremor defined as:
 Tremor causing significant limitation in daily activities; and  Inadequate control by maximal dosage of medication for at least three months before implant.
Based on review of available data, the Company may consider unilateral or bilateral deep brain stimulation (DBS) of the globus pallidus or subthalamic nucleus when patient selection criteria are met to be eligible for coverage.
Patient Selection Criteria Coverage eligibility will be considered for unilateral or bilateral deep brain stimulation (DBS) of the globus pallidus or subthalamic nucleus when all of the following criteria are met:  Parkinson disease and ALL of the following: o A good response to levodopa; AND o Motor complications not controlled by pharmacologic therapy; AND o One of the following:  A minimum score of 30 points on the motor portion of the Unified Parkinson Disease Rating Scale when the patient has been without medication for approximately 12 hours OR  Parkinson disease for at least 4 years be important in the pathogenesis of cluster headaches. Alterations in hormonal or serotonergic function may also play a role. Treatment of cluster headaches includes pharmacologic interventions for acute episodes and prophylaxis, sphenopalatine ganglion (SPG) blockade, and surgical procedures such as percutaneous SPG radiofrequency rhizotomy, and gamma knife radiosurgery of the trigeminal nerve.
Neurologic and Psychiatric Disorders
The role of DBS in treatment of other treatment-resistant neurologic and psychiatric disorders, particularly epilepsy, Tourette syndrome, major depressive disorders, and obsessive-compulsive disorder, is also being investigated. Ablative procedures are irreversible and, though they have been refined, remain controversial treatments for intractable illness. Interest has shifted to neuromodulation through DBS of nodes or targets within neural circuits involved in these disorders. Currently, a variety of target areas are being studied.
FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)
In 1997, the Activa ® ‡ Tremor Control System (Medtronic) was cleared for marketing by the U.S. FDA for deep brain stimulation. The Activa Tremor Control System consists of an implantable neurostimulator, a deep brain stimulator lead, an extension that connects the lead to the power source, a console programmer, a software cartridge to set electrical parameters for stimulation, and a patient control magnet, which allows the patient to turn the neurostimulator on and off, or change between high and low settings.
The original FDA-labeled indications for Activa were limited to unilateral implantation of the device for the treatment of tremor, but, in 2002, FDA-labeled indications were expanded to include bilateral implantation as a treatment to decrease the symptoms of advanced Parkinson disease not controlled by medication. In 2003, the labeled indications were further expanded to include "…unilateral or bilateral stimulation of the internal globus pallidus or subthalamic nucleus to aid in the management of chronic, intractable (drug refractory) primary dystonia, including generalized and/or segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients seven years of age or above." This latter indication was cleared for marketing by FDA through the humanitarian device exemption (HDE) process. In 2017, the indications for Parkinson disease were modified to include "adjunctive therapy in reducing some of the symptoms in individuals with levodopa-responsive Parkinson's Disease of at least 4 years' duration that are not adequately controlled with medication."
In 2009, the Reclaim ® ‡ device (Medtronic), a deep brain stimulator, was cleared for marketing by FDA through the HDE process for the treatment of severe obsessive-compulsive disorder.
In 2014, the Brio Neurostimulation System (now called Infinity; St. Jude Medical Neuromodulation) was cleared for marketing by FDA for the treatment of Parkinsonian tremor. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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In 2016, the St. Jude Medical's Infinity DBS device with directional leads was approved by FDA. The directional leads enable the clinician to "steer" current to different parts of the brain. This tailored treatment reduces side effects. The Infinity system can be linked to Apple's iPod Touch and iPad Mini.
In December 2017, a second system with directional leads, the Vercise Deep Brain Stimulation System (Boston Scientific), was approved by FDA. This system is to be used as an adjunctive therapy from reducing motor symptoms of moderate-to-advanced levodopa-responsive PD inadequately controlled with medication alone.
FDA product code: MHY.
Centers for Medicare and Medicaid Services (CMS)
Effective for services furnished on or after April 1, 2003, Medicare covers unilateral or bilateral thalamic ventralis intermedius nucleus (VIM) DBS for the treatment of ET and/or parkinsonian tremor and unilateral or bilateral STN or globus pallidus interna (GPi) DBS for the treatment of PD when the following conditions are met.
1. DBS devices must be FDA-approved devices for "DBS or devices used in accordance with FDAapproved protocols governing Category B Investigational Device Exemption (IDE) DBS clinical trials." 2. For thalamic VIM DBS, patients must meet all of the following criteria:
a. "Diagnosis of ET based on postural or kinetic tremors of hand(s) without other neurologic signs, or diagnosis of idiopathic PD (presence of at least 2 cardinal PD features (tremor, rigidity or bradykinesia)) which is of a tremor-dominant form. b. Marked disabling tremor of at least level 3 or 4 on the Fahn-Tolosa-Marin Clinical Tremor Rating Scale (or equivalent scale) in the extremity intended for treatment, causing significant limitation in daily activities despite optimal medical therapy. c. Willingness and ability to cooperate during conscious operative procedure, as well as during postsurgical evaluations, adjustments of medications and stimulator settings." 3. For STN or GPi DBS, patients must meet all of the following criteria:
a. "Diagnosis of PD based on the presence of at least 2 cardinal PD features (tremor, rigidity or bradykinesia Structural lesions such as basal ganglionic stroke, tumor or vascular malformation as etiology of the movement disorder.
Previous movement disorder surgery within the affected basal ganglion.
Significant medical, surgical, neurologic or orthopedic co-morbidities contraindicating DBS surgery or stimulation."
Rationale/Source
Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to functionincluding benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.
To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and longterm effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.
ESSENTIAL TREMOR AND TREMOR IN PARKINSON DISEASE
Unilateral Stimulation of the Thalamus
This section was originally informed by a 1997 TEC Assessment that focused on unilateral DBS of the thalamus as a treatment of tremor. The Assessment concluded:
 Tremor suppression was total or clinically significant in 82% to 91% of operated sides in 179 patients who underwent implantation of thalamic stimulation devices. Results were durable for up to 8 years, and adverse effects of stimulation were reported as mild and largely reversible.
 These results were at least as good as those associated with thalamotomy. An additional benefit of DBS is that recurrence of tremor may be managed by changes in stimulation parameters. 
Directional Deep Brain Stimulation
Two new DBS systems with directional leads are currently available (approved by the FDA in 2016 and 2017). Directional leads potentially enable clinicians to target more specific areas of the brain to be treated with the direct current. Published evidence consists of several small observational studies, with sample sizes ranging from 7 to 13. The studies showed that patients experienced improved tremor scores and improved quality of life (QOL). Compared with historical data from conventional DBS systems, directional DBS widened the therapeutic window and achieved beneficial effects using lower current level.
Comparative, larger studies are needed to support the conclusions from these small studies. Data from a large study of 292 patients are expected in 2018.
Section Summary: Essential Tremor and Tremor in Parkinson Disease
A TEC Assessment concluded there was sufficient evidence that DBS of the thalamus results in clinically significant tremor suppression and that outcomes after DBS were at least as good as thalamotomy. Subsequent studies reporting long-term follow-up have supported the conclusions of the Assessment and found that tremors were effectively controlled 5 to 6 years after DBS. An earlier (2006) systematic review included both RCTs and observational studies; reviewers examined the literature on subthalamic stimulation for patients with PD who had failed medical management. Twenty studies, primarily uncontrolled cohorts or case series, were included in the meta-analysis. Subthalamic stimulation was found to improve ADLs by 50% over baseline, as measured by the UPDRS-II (decrease of 13.35 points out of 52). There was a 28-point decrease in the UPDRS-III score (out of 108), indicating a 52% reduction in the severity of motor symptoms that occurred while the patient was not taking medication. A strong relation was found between the preoperative dose response to levodopa and improvements in both the UPDRS-II and -III scores. The analysis found a 56% reduction in medication use, a 69% reduction in dyskinesia, and a 35% improvement in QOL with subthalamic stimulation.
SYMPTOMS ASSOCIATED WITH PARKINSON DISEASE
In 2007, a meta-analysis by Appleby et al found that the rate of suicidal ideation/suicide attempts associated with DBS for PD ranged from 0.3% to 0.7%. The completed suicide rate ranged from 0.16% to 0.32%. In light of the rate of suicide in patients treated with DBS, reviewers argued for prescreening for suicide risk.
Parkinson Disease With Early Motor Complications
In 2013, Schuepbach et al published an RCT evaluating DBS in patients with PD and early motor complications. Key eligibility criteria included age 18 to 60 years, disease duration of at least 4 year, improvement of motor signs of at least 50% with dopaminergic medication, and PD disease severity below stage 3 in the on-medication condition. At total of 251 patients enrolled, 124 of whom were assigned to DBS plus medical therapy and 127 to medical therapy alone. Analysis was intention to treat and blinded outcome assessment was done at baseline and 2 years. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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The primary end point was mean change from baseline to 2 years in the summary index of the Parkinson Disease Questionnaire (PDQ-39), which has a maximum score is 39 points, with higher scores indicating higher QOL. Mean baseline scores on the PDQ-39 were 30.2 (SD=1.3) in the DBS plus medical therapy group and 30.2 (SD=1.2) in the medical therapy only group. At 2 years, the mean score increased by 7.8 points (SD=1.2) in the DBS plus medical therapy group and decreased by 0.2 points (SD=1.1) in the medical therapy only group. There was a significant difference between groups in the mean change, 8.0 (SD=1.6) (p=0.002). There were also significant between-group differences in major secondary outcomes, favoring the DBS plus medical therapy group (p<0.01 on each). These outcomes included severity of motor signs, ADLs, severity of treatment-related complications, and the number of hours with good mobility and no troublesome dyskinesia. The first 3 secondary outcomes were assessed using UPDRS subscales.
Regarding medication use, the levodopa-equivalent daily dose was reduced by 39% in the DBS plus medical therapy group and increased by 21% in the medical therapy only group.
Sixty-eight patients in the DBS plus medical therapy group and 56 in the medical therapy only group experienced at least 1 serious adverse event (SAE). This included 26 SAEs in the DBS group that were surgery-or device-related; reoperation was necessary in 4 patients.
GPi vs STN Stimulation
A number of meta-analyses have compared the efficacy of GPi and STN stimulation in PD patients. One 2016 meta-analysis included only RCTs comparing the 2 types of stimulation in patients with advanced PD and considered a range of outcomes. This review, by , included RCTs evaluating patients with PD who were responsive to levodopa, had at least 6 months of follow-up, and reported at least 1 of the following outcome measures: UPDRS-III, Beck Depression InventoryII (BDI), levodopa-adjusted dose (LED), neurocognitive status, or QOL. Ten RCTs met eligibility criteria and were included in the quantitative synthesis. After 6 months, there were no significant differences in the UPDRS-III scores between the GPi and STN groups for patients in the off-medication/on-simulation state (5 studies; MD = -1.39; 95% CI, -3.70 to 0.92) or the on-medication/on-stimulation state (5 studies; MD = -0.37; 95% CI, -2.48 to 1.73). At the 12-and 24-month follow-up, only 1 to 3 studies reported data on the UPDRS-III score. A pooled analysis of LED, there was a significant difference between the GPi and STN groups, favoring STN (6 studies; MD=0.60; 95% CI, 0.46 to 0.74). However, the analysis of BDI-II scores favored the GPI group (4 studies; MD = -0.31; 95% CI, -0.51 to -0.12). Other meta-analyses had similar mixed findings and none concluded that 1 type of stimulation was clearly better than the other for patients with advanced PD.
Section Summary: Symptoms Associated With Parkinson Disease
A number of RCTs and systematic reviews of the literature have been published. A TEC Assessment concluded that studies on DBS of the GPi or STN have consistently demonstrated clinically significant improvements in outcomes (eg, neurologic function). Other systematic reviews have also found significantly better outcomes after DBS than with a control intervention. One RCT compared the addition of DBS to medical therapy with medical therapy alone in patients with levodopa-responsive PD of at least 4 years in duration and uncontrolled motor symptoms. The trial found that that QOL at 2 years (eg, motor disability, No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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motor complications) was significantly higher when DBS was added to medical therapy. Meta-analyses of RCTs comparing GPi and STN have had mixed findings and did not show that 1 type of stimulation was clearly superior to the other.
PRIMARY DYSTONIA DBS for the treatment of primary dystonia received U.S. FDA approval through the HDE process in 2003. The HDE approval process is available for conditions that affect fewer than 4000 Americans per year. According to this approval process, the manufacturer is not required to provide definitive evidence of efficacy, but only probable benefit. The approval was based on the results of DBS in 201 patients represented in 34 manuscripts. Three studies reported at least 10 cases of primary dystonia. In these studies, clinical improvement with DBS ranged from 50% to 88%. A total of 21 pediatric patients were studied; 81% were older than age 7 years. Among these patients, there was a 60% improvement in clinical scores. As noted in the analysis of risk and probable benefit, the only other treatment options for chronic refractory primary dystonia are neurodestructive procedures. DBS provides a reversible alternative.
In 2017, Moro et al published a systematic review of literature published through November 2015 on primary dystonia (also known as isolated dystonia). Reviewers included studies with at least 10 cases. Fiftyeight articles corresponding to 54 unique studies were identified; most involved bilateral DBS of the GPi. There were only 2 controlled studies, 1 RCT (Volkmann et al; described below) and 1 study that included a double-blind evaluation with and without stimulation. Twenty-four studies reported data using the BurkeFahn-Marsden Dystonia Rating Scale (BFMDRS) and were included in a meta-analysis. These studies enrolled a total of 523 patients (mean per study, 22 patients) and had a mean follow-up of 32.3 months (range, 6-72 months). In a pooled analysis of BFMDRS motor scores (scale range, 0-120; higher scores indicate more severe dystonia) from 24 studies, the mean increase in scores at 6 months compared with baseline was 23.8 points (95% CI, 18.5 to 29.1 points). The mean increase in the motor score at last followup compared with baseline was 26.6 points (95% CI, 22.4 to 30.9 points). The mean percentage improvement was 59% at 6 months and 65% at last follow-up. Fourteen studies reported BFMDRS disability scores (scale range, 0-30). Compared with baseline, the mean absolute change in the score was 4.8 points (95% CI, 3.1 to 6.6 points) at 6 months and 6.4 points (95% CI, 5.0 to 7.8 points) at last follow-up. The mean percentage improvement was 44% at 6 months and 59% at last follow-up.
The RCT, which was an industry-sponsored, patient-and observer-blinded evaluation of pallidal neurostimulation in subjects with refractory cervical dystonia, was published by Volkmann et al in 2014. The trial included 62 adults with cervical dystonia of at least 3 years in duration, a severity score of at least 15 on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and an unsatisfactory response to botulinum toxin injection and oral medication. Patients were randomized to DBS (n=32) or to sham stimulation (n=30). The primary outcome was change in the TWSTRS severity score at the end of the blinded study period ( No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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3.8 points (95% CI, 1.8 to 5.8 points; p=0.024). Findings were mixed on the prespecified secondary outcomes. There was significantly greater improvement in the neurostimulation than in the sham group on the TWSTRS disability score and the Bain Tremor Scale score, but not on the TWSTRS pain score or the Craniocervical Dystonia Questionnaire-24 score. During the 3-month blinded study period, 22 adverse events were reported in 20 (63%) patients in the neurostimulation group and 13 adverse events were reported in 12 (40%) patients in the sham group. Of these 35 adverse events, 11 (31%) were serious. Additionally, 40 adverse events, 5 of which were serious, occurred during 9 months of the open-label extension period. During the study, 7 patients experienced dysarthria (ie, slightly slurred speech), which was not reversible in 6 patients.
Section Summary: Primary Dystonia
A review prepared for FDA and a 2017 systematic review have evaluated literature on DBS for primary dystonia. There are numerous small case series and 1 RCT. The RCT found that severity scores improved more after active than after sham stimulation. A pooled analysis of 24 studies, mainly uncontrolled, found improvements in motor scores and disability scores after 6 months and at last follow-up (mean, 32 months).
TARDIVE DYSKINESIA AND TARDIVE DYSTONIA
Stimulation of the GPi was examined as a treatment for tardive dyskinesia in a 2007 multicenter case series, with a double-blind evaluation at 6 months (comparison of symptoms in the on and off positions). The trial was stopped early due to successful treatment (>40% improvement at 6 months) in the first 10 patients. In the double-blind evaluation of these patients, stimulation was associated with a mean decrease of 50% in the symptom score when the device was on versus off.
Outcomes on motor function, QOL, and mood in a series 9 patients treated with DBS of the GPi for tardive dystonia were reported by Gruber et al in 2009. One week and 3 to 6 months after surgery, BFMDRS motor scores were improved by 56.4% and 74.1%, BFMDRS disability scores by 62.5% and 88.9%, and Abnormal Involuntary Movement Scale (AIMS) scores by 52.3% and 69.5%, respectively. At last follow-up (mean, 41 months; range, 18-90 months), BFMDRS motor scores were reduced compared with presurgical assessment by 83%, BFMDRS disability score by 67.7%, and AIMS scores by 78.7%.
Pouclet-Courtemanche et al (2016) reported on a case series of 19 patients with severe pharmaco-resistant tardive dyskinesia treated with DBS. Patients were assessed after 3, 6, and 12 months after the procedure. At 6 months, all patients had experienced greater than 40% reduction in symptoms as measured on the Extrapyramidal Symptoms Rating Scale (ESRS). At 12 months, the mean decrease in ESRS score was 58% (range, 21%-81%).
Section Summary: Tardive Dyskinesia and Tardive Dystonia
Evidence for the use of DBS to treat tardive syndromes consists of case series. One study of DBS in patients with tardive dyskinesia included a double-blind evaluation of DBS at 6 months. Symptoms decreased more with the device turned on but the study was small (10 patients were evaluated) and No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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included only patients with DBS for 6 months. Two subsequent case series included 9 and 19 patients, respectively, and reported favorable results with DBS treatment. Additional studies evaluating more patients, especially RCTs or other controlled studies, are needed to provide greater certainty concerning the efficacy of DBS for this population.
EPILEPSY
Systematic Reviews
Two systematic reviews on the use of DBS for drug-resistant epilepsy, both published in 2018, assessed many of the same studies. The larger review, by Li et al (2018), identified 10 RCTs and 48 uncontrolled studies. The literature search date was not reported. Meta-analyses were not performed. Summaries of the studies were discussed by area of the brain targeted by DBS. A review of the studies showed that DBS might be effective in reducing seizures when DBS targets the anterior nucleus of the thalamus or the hippocampus. Across studies, more than 70% of patients experienced a reduction in seizures by 50% or more. However, there were very few RCTs and the observational studies had small sample sizes. Individual responses varied, depending on seizure syndrome, presence or absence of structural abnormalities, and electrode position. Results were inconclusive when DBS targeted the centromedian nucleus of the thalamus, the cerebellum, and the subthalamic nuclei. Safety data on DBS were limited due to the small population sizes. The RCT in which DBS targeted the anterior nucleus of the thalamus (Fisher et al [2010] described below) reported paresthesias (23%), implant site pain (21%), and implant site infection (13%). Reviewers concluded that more robust clinical trials would be needed.
Randomized Controlled Trials
Fisher et al (2010) conducted a U.S. multicenter, double-blind, randomized trial, Stimulation of the Anterior Nuclei of the Thalamus for Epilepsy (SANTE) (see Table 1 ). Included were 110 patients, ages 18 to 65 years, who experienced at least 6 partial seizures (including secondarily generalized seizures) per month, but no more than 10 per day. (An additional 47 patients were enrolled in the trial but did not undergo implantation.) At least 3 antiepileptic drugs must have failed to produce adequate seizure control before baseline, with 1 to 4 antiepileptic drugs used at the time of study entry. Patients were asked to keep a daily seizure diary during treatment. All patients received DBS device implantation, with half the patients randomized to stimulation (n=54) and half to no stimulation (n=55) during a 3-month blinded phase; thereafter all patients received unblinded stimulation. Baseline monthly median seizure frequency was 19.5. During the first and second months of the blinded phase, the difference in seizure reduction between stimulation on (-42.1%) and stimulation off (-28.7%) did not differ significantly. In the last month of the blinded phase, the stimulated group had a significantly greater reduction in seizures (-40.4%) than the control group (-14.5%; p=0.002; see Table 2 ).
Troster et al (2017) assessed neuropsychological adverse events from the SANTE trial during the 3-month blinded phase, and at 7-year follow-up during the open-label noncomparative phase (see Table 2 ). At baseline, there were no differences in depression history between groups. During the 3-month blinded phase of the trial, depression was reported in 8 (15%) patients from the stimulation group and in 1 (2%) No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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patient from the no stimulation group (p=0.02). At 7-year follow-up, after the treatment groups had been combined, there was no statistically significant difference in Profile of Mood State depression score compared with baseline. Memory adverse events also occurred at significantly different rates between the treatment groups during the blinded phase (7 in the active group, 1 in the control group; p=0.03). At 7-year follow-up, most cognitive function tests did not improve over baseline measurements.
Cukiert et al (2017) conducted a double-blind, placebo-controlled randomized trial evaluating 16 patients with refractory temporal lobe epilepsy (see Table 1 ). All patients underwent DBS device implantation, and were followed for 6 months. Patients were seen weekly to receive the treatment or placebo. To maintain double-blind status, programming was performed by a nontreating assistant. Patients kept a seizure diary during the study period. Patients were considered seizure-free if no seizures occurred during the last 2 months of the trial. Responders were defined as patients experiencing a reduction of 50% or more in frequency reduction. Results are summarized in Table 2 . 
Observational Studies
Long-term outcomes of the SANTE trial were reported by . The uncontrolled openlabel portion of the trial began after 3 months and, beginning at 13 months, stimulation parameters could be adjusted at the clinician's discretion. Of the 110 implanted patients, 105 (95%) completed the 13-month follow-up, 98 (89%) completed the 3-year follow-up, and 83 (75%) completed 5 years. Among patients with No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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at least 70 days of diary entries, the median change in seizure frequency from baseline was 41% at 1 year and 69% at 5 years (p<0.001 for both). During the trial, 39 (35%) of 110 patients had a device-related serious adverse event, most of which occurred in the first months after implantation. They included implantsite infection (10% of patients) and lead(s) not within target (8.2% of patients). Seven deaths occurred during the trial and none was considered to be device-related. Depression was reported in 41 (37%) patients following implant; in 3 cases, it was considered device-related. Memory impairment (nonserious) was reported in 30 (27%) patients during the trial, half of whom had a history of the condition. Although some patients appeared to benefit from treatment during the extended follow-up phase, the difference between groups in the blinded portion of the trial, while significant, was modest overall.
Kim et al (2017) conducted a retrospective chart review of 29 patients with refractory epilepsy treated with DBS. Patients' mean age was 31 years, they had had epilepsy for a mean of 19 years, and had a mean preoperative frequency of tonic-clonic seizures of 27 per month. Mean follow-up was 6.3 years. Median seizure reduction from baseline was 71% at year 1, 74% at year 2, and ranged from 62% to 80% through 11 years of follow-up. Complications included 1 symptomatic intracranial hemorrhage, 1 infection requiring removal and reimplantation, and 2 lead disconnections.
Section Summary: Epilepsy
A systematic review identified several RCTs and many observational studies in which DBS was evaluated for the treatment of epilepsy. The largest RCT consisted of a 3-month blinded phase in which patients were randomized to stimulation or no stimulation. After the randomized phase, all patients received stimulation and were followed for 13 additional months. Findings in the first 3 months were mixed: patients reported significantly fewer seizures in the third month, but not in the first or second month. In the uncontrolled follow-up period of the RCT and in many small observational studies, patients reported fewer seizures compared with baseline, however, without a control group, interpretation of results is limited. Adverse events, including device-related serious adverse events were reported in about one-third of patients. The risk-benefit ratio is uncertain. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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TOURETTE SYNDROME Several systematic reviews of the literature on DBS for Tourette syndrome have been published. Most recent systematic reviews (ie, those published in 2015-2017) qualitatively described the literature. Only Baldermann et al (2016) conducted pooled analyses of study data. That review identified 57 studies on DBS for Tourette syndrome, four of which were randomized crossover studies. The studies included a total of 156 cases. Twenty-four studies included a single patient and 4 had sample sizes of 10 or more (maximum, 18 patients). Half of the patients (n=78) received thalamus stimulation and the next most common areas of stimulation were the GPi anteromedial part (n=44) and post ventrolateral part (n=20). Two of the RCTs used thalamic stimulation, one used bilateral globus pallidus stimulation, and one used both. The primary outcome was the Yale Global Tic Severity Scale (YGTSS). In a pooled analysis of within-subject pre-post data, there was a median improvement of 53% in YGTSS score, a decline from a median score of 83 to 35 at last follow-up. Moreover, 81% of patients showed at least a 25% reduction in YGTSS score and 54% showed improvements of 50% or more. In addition, data were pooled from the 4 crossover RCTs: 27 patients received DBS and 27 received a control intervention. Targets included the thalamus and the globus pallidus. In the pooled analysis, there was a statistically significant between-group difference, favoring DBS (SMD=0.96; 95% CI, 0.36 to 1.56). Reviewers noted that the effect size of 0.96 would be considered be large. The crossover RCT with the largest sample size was published by Kefalopoulou et al (2015) . The doubleblind trial included 15 patients with severe medically refractory Tourette syndrome; all received bilateral GPi surgery for DBS and were randomized to the off-stimulation phase first or the on-stimulation phase first for 3 months, followed by the opposite phase for the next 3 months. Of the 15 receiving surgery, 14 were randomized and 13 completed assessments after both on and off phases. For the 13 trial completers, mean YGTSS scores were 80.7 in the off-stimulation phase and 68.3 in the on-stimulation phase. The mean difference in YGTSS scores indicated an improvement of 12.4 points (95% CI, 0.1 to 24.7 points), which was statistically significant (p=0.048) after Bonferroni correction. There was no significant between-group difference in YGTSS scores for patients randomized to the on-stimulation phase first or second. Three serious adverse events were reported, 2 related to surgery and 1 related to stimulation. Reviewers noted that the most effective target of the brain for DBS in patients with Tourette syndrome needs additional study. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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Section Summary: Tourette Syndrome A number of uncontrolled studies,4 crossover RCTs, and several systematic reviews have been published. Most studies, including the RCTs, had small sample sizes (ie, ≤15 patients) and used a variety of DBS targets. A 2015 meta-analysis suggested that DBS might improve outcomes in patients with Tourette syndrome. However, the optimal target for DBS is not known and additional controlled studies in larger numbers of patients are needed. Another research group from Europe published 2 case series (potentially overlapping) on use of DBS for the ipsilateral posterior hypothalamus in patients with chronic cluster headache. Stimulation was reported to result in long-term pain relief (1-26 months of follow-up) without significant adverse events in 16 patients with chronic cluster headaches and in 1 patient with neuralgiform headache; treatment failed in the 3 patients who had atypical facial pain.
CLUSTER HEADACHE AND FACIAL PAIN
Section Summary: Cluster Headache and Facial Pain
Several case series and a crossover RCT have been published on use of DBS for cluster headache or facial pain. The RCT included 11 patients; there were no significant differences between groups receiving active and sham stimulation. Additional RCTs or controlled studies are needed. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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very low probability of success if the trial was completed as planned). A systematic review by Mosley et al (2015) identified an RCT on DBS for depression 44 ; this trial is described next.
Randomized Controlled Trials
An industry-sponsored, double-blind RCT evaluating DBS targeting the ventral capsule/ventral striatum in patients with chronic treatment-resistant depression was published by Dougherty et al (2015) . The trial included 30 patients with a major depressive episode lasting at least 2 years and inadequate response to at least 4 trials of antidepressant therapy. Participants were randomized to 16 weeks of active (n=16) or to sham (n=14) DBS, followed by an open-label continuation phase. One patient, who was assigned to active treatment, dropped out during the blinded treatment phase. The primary outcome was clinical response at 16 weeks, defined as 50% or more improvement from baseline on Montgomery-Asberg Depression Rating Scale (MADRS) score. A response was identified in 3 (20%) of 15 patients in the active treatment group and in 2 (14%) of 14 patients in the sham control group (p=0.53). During the blinded treatment phase, psychiatric adverse events occurring more frequently in the active treatment group included worsening depression, insomnia, irritability, suicidal ideation, hypomania, disinhibition, and mania. Psychiatric adverse events occurring more frequently in the sham control group were early morning awakening and purging. Findings of this trial did not support a conclusion that DBS is effective for treating treatment-resistant depression. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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Section Summary: Treatment-Resistant Depression A number of case series and several RCTs evaluating DBS in patients with treatment-resistant depression have been published. Two RCTs were terminated for futility. Another RCT did not find a statistically significant difference between groups in the primary outcome (clinical response) and adverse psychiatric events occurred more frequently in the treatment group than in the control group. More recently, a controlled crossover trial randomized patients to active or to sham stimulation after a year of open-label stimulation. There was a greater reduction in symptom scores after active stimulation, but only in patients who were responders in the open-label phase; these findings might not be generalizable.
OBSESSIVE-COMPULSIVE DISORDER
Several systematic reviews evaluating DBS for obsessive-compulsive disorder (OCD) have been published. Two of these reviews included meta-analyses and pooled study findings. Kisely et al (2014) included only double-blind RCTs of active vs sham DBS. Five trials (total N=50 patients) met eligibility criteria and data on 44 patients were available for meta-analysis. Three were parallel-group RCTs with or without a crossover phase and 2 were only crossover trials. The site of stimulation was the anterior limb of the internal capsule (3 studies), the nucleus accumbens (1 study), and the STN (1 study). Duration of treatment ranged from 2 to 12 weeks. All studies reported scores on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), which is a 10-item clinician-rated scale, in which higher ratings reflect more intense symptoms, and a score of 24 or more (of a possible 40) indicates severe illness. Most studies designate a therapeutic response as a reduction in Y-BOCS score of 35% or more from the pretreatment baseline, with a reduction of 25% to 35% considered a partial response. Only 1 of the 5 studies compared the proportion of responders on the Y-BOCS as an outcome measure and that study did not find a statistically significant difference between active and sham stimulation groups. All studies reported the outcome measure, mean reduction in Y-BOCS score. When data from the 5 studies were pooled, there was a statistically significant reduction in the mean Y-BOCS in the active vs the sham group (MD = -8.49; 95% CI, -12.18 to -4.80). The outcome measure, however, does not permit conclusions on whether the between-group difference is clinically meaningful. Trial authors reported 16 serious adverse events including 1 cerebral hemorrhage and 2 infections requiring electrode removal. Additionally, nonserious transient adverse events were reported, including 13 reports of hypomania, 6 of increase in depressive or anxious symptoms, and 6 of headaches.
A meta-analysis by Alonso et al (2015) No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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of DBS stimulation but could not draw conclusions about stimulation to any particular region or about the safety or efficacy of DBS for OCD compared with sham stimulation or other therapy.
Section Summary: Obsessive-Compulsive Disorder
The literature on DBS for OCD consists of several RCTs and a number of uncontrolled studies. Most studies had small sample sizes. Only 1 of the 5 RCTs identified in a 2015 meta-analysis reported the outcome measure of greatest interestclinically significant change in Y-BOCS scores. Uncontrolled data have suggested improvements in OCD symptoms after DBS treatment, but have also identified a substantial number of adverse events. Additional blinded controlled studies are needed to draw conclusions about the impact of DBS on the net health benefit.
OTHER INDICATIONS
The evidence on use of DBS for anorexia nervosa, alcohol addiction, Alzheimer disease, Huntington disease, and chronic pain consists of small case series. These case series provide inadequate evidence on which to assess efficacy.
SUMMARY OF EVIDENCE
For individuals who have essential tremor or tremor in PD who receive DBS of the thalamus, the evidence includes a systematic review and case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The systematic review (a TEC Assessment) concluded that there was sufficient evidence that DBS of the thalamus results in clinically significant tremor suppression and that outcomes after DBS were at least as good as thalamotomy. Subsequent studies reporting longterm follow-up have supported the conclusions of the TEC Assessment and found that tremors were effectively controlled 5 to 6 years after DBS. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
For individuals who have symptoms (eg, speech, motor fluctuations) associated with PD (advanced or >4 years in duration with early motor symptoms) who receive DBS of the GPi or STN, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. One of the systematic reviews (a TEC Assessment) concluded that studies evaluating DBS of the GPi or STN have consistently demonstrated clinically significant improvements in outcomes (eg, neurologic function). Other systematic reviews have also found significantly better outcomes after DBS than after a control intervention. An RCT in patients with levodopa-responsive PD of at least 4 years in duration and uncontrolled motor symptoms found that quality of life at 2 years was significantly higher when DBS was provided in addition to medical therapy. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
For individuals who have primary dystonia who receive DBS of the GPi or STN, the evidence includes systematic reviews, an RCT, and case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A pooled analysis of 24 studies, mainly uncontrolled, found improvements in motor scores and disability scores after 6 months and at last follow-up (mean, 32 months).
A double-blind RCT found that severity scores improved more after active than after sham stimulation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.
For individuals who have tardive dyskinesia or tardive dystonia who receive DBS, the evidence includes case series, one of which included a double-blind comparison of outcomes when the DBS device was turned on versus off. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatmentrelated morbidity. Few studies were identified and they had small sample sizes (range, 9-19 patients).
Additional studies, especially RCTs or other controlled studies, are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.
For individuals who have epilepsy who receive DBS, the evidence includes 2 systematic reviews of RCTs and many observational studies. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Two RCTs were identified. The larger reported that DBS had a positive impact during some parts of the blinded trial phase but not others, and a substantial number of adverse events (in >30% of patients). The smaller RCT (N=16) showed a benefit with DBS. Many small observational studies reported fewer seizures compared with baseline, however, without control groups, interpretation of these results is limited. Additional trials are required to determine the impact of DBS on patient outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.
For individuals who have multiple sclerosis who receive DBS, the evidence includes an RCT. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. One RCT with 10 multiple sclerosis patients is insufficient evidence on which to draw conclusions about the efficacy of DBS in this population. Additional trials are required. The evidence is insufficient to determine the effects of the technology on health outcomes.
For individuals who have Tourette syndrome who receive DBS, the evidence includes crossover RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatmentrelated morbidity. Several small (≤15 patients) crossover trials and a 2015 meta-analysis have suggested that DBS may improve outcomes in patients with Tourette syndrome. However, the optimal target of the brain for DBS is unknown, so additional controlled studies in larger numbers of patients are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.
For individuals who have cluster headaches or facial pain who receive DBS, the evidence includes a randomized crossover study and case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. In the randomized study, the between-group difference in No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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response rates did not differ significantly between active and sham stimulation phases. Additional RCTs or controlled studies are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.
For individuals who have treatment-resistant depression who receive DBS, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatmentrelated morbidity. The only double-blind, parallel-group RCT in patients with depression did not find that DBS significantly increased the response rate compared with sham; 2 other RCTs were stopped due to futility. A crossover controlled trial randomized patients to active or to sham stimulation after a year of openlabel stimulation. There was a greater reduction in symptom scores after active stimulation, but only in patients who were responders in the open-label phase; these findings might not be generalizable. The evidence is insufficient to determine the effects of the technology on health outcomes.
For individuals who have obsessive-compulsive disorder who receive DBS, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Among the RCTs on DBS for obsessive-compulsive disorder, only one has reported the outcome of greatest clinical interest (therapeutic response rate), and that trial did not find a statistically significant benefit for DBS compared with sham treatment. The evidence is insufficient to determine the effects of the technology on health.
For individuals who have anorexia nervosa, alcohol addiction, Alzheimer disease, Huntington disease, or chronic pain who receive DBS, the evidence includes case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. RCTs are needed to evaluate the efficacy of DBS for these conditions. The evidence is insufficient to determine the effects of the technology on health outcomes. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
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B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease. For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors. ‡ Indicated trademarks are the registered trademarks of their respective owners.
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